Skip to main content
Innate Pharma logo

Innate Pharma — Investor Relations & Filings

Ticker · IPH ISIN · FR0010331421 LEI · 9695002Y8420ZB8HJE29 PA Manufacturing
Open in API
Filings indexed 1,403 across all filing types
Latest filing 2023-06-16 Legal Proceedings Report
Country FR France
Listing PA IPH

About Innate Pharma

http://www.innate-pharma.com/

Innate Pharma is a clinical-stage, oncology-focused biotechnology company that develops immunotherapies for cancer patients. The company's scientific approach is centered on leveraging the innate immune system, particularly Natural Killer (NK) cells, to create novel treatments. Its innovative pipeline is composed of antibody-based therapeutics, including first-in-class monoclonal antibodies, antibody-drug conjugates (ADCs), and multi-specific NK cell engagers based on its proprietary ANKET® platform. Key clinical programs include lacutamab (anti-KIR3DL2), monalizumab (anti-NKG2A) in partnership with AstraZeneca, and a portfolio of NK cell engagers targeting various hematological malignancies and solid tumors.

Recent filings

Filing Released Lang Actions
Informations privilégiées / Autres communiqués
Legal Proceedings Report Classification · 1% confidence The document is a press release dated June 16, 2023, announcing updated efficacy results from the Phase 2 TELLOMAK clinical trial for the drug lacutamab, presented at the 17th International Conference on Malignant Lymphoma (ICML). It details clinical data, quotes management (Medical Director and an external physician), and provides background on the drug and the trial structure. This format—a formal announcement of clinical trial data and business updates outside of a mandatory periodic report (like 10-K or IR)—is characteristic of an Earnings Release (ER) or a general press release detailing operational/clinical progress. Since it focuses heavily on clinical trial results and scientific updates rather than just summarizing quarterly financial performance highlights, it aligns best with an announcement of significant operational/clinical progress. However, given the options, this type of announcement, which is often released concurrently with or shortly after financial reporting periods to update investors on pipeline progress, is frequently categorized as an Earnings Release (ER) if it's a major update, or sometimes as a Regulatory Filing (RNS) if it's purely scientific. Since it contains specific efficacy data updates and quotes from management regarding future expectations, it functions as a key investor update. In many classification schemes, detailed clinical trial updates released via press release fall under the 'Earnings Release' umbrella when they are the primary focus of the communication, or sometimes 'Regulatory Filing' (RNS) if it's a general update. Given the high level of detail on clinical efficacy (which often accompanies or substitutes for a formal earnings discussion on R&D progress), 'ER' is a strong candidate, but 'RNS' is the safest fallback for non-standard announcements. Reviewing the definitions, 'ER' is for initial announcement of periodical financial results (key highlights only). This is a clinical update, not a financial highlight summary. 'RNS' is the general regulatory announcement fallback. Since this is a detailed scientific/clinical update released via press release, 'RNS' (Regulatory Filings / General regulatory announcements) is the most appropriate general category for non-standard, material corporate news that isn't a specific report type like 10-K or IR.
2023-06-16 French
Inside Information / Other news releases
Earnings Release Classification · 1% confidence The document is a press release dated June 16, 2023, announcing interim efficacy results from the TELLOMAK Phase 2 clinical study for the drug lacutamab in advanced Mycosis Fungoides. It details clinical data (ORR, response rates), quotes management and external experts, and provides background on the drug and the trial. This format—a formal announcement of recent scientific/clinical progress, often released concurrently with a presentation at a conference—is characteristic of an Earnings Release (ER) or a general press release related to operational/clinical updates. Since it focuses purely on clinical trial results and does not contain the full, structured financial statements of a quarterly or annual report, nor is it a transcript or a formal regulatory filing like a 10-K, the most appropriate classification is Earnings Release (ER), as these announcements often serve as the primary vehicle for communicating period-specific operational highlights, even if the period is defined by a clinical milestone rather than a fiscal quarter end. It is not a formal 'Report Publication Announcement' (RPA) because it contains the substantive results, not just a notice that a report is available. FY 2023
2023-06-16 English
INNATE PHARMA S.A. 6-K
Foreign Filer Report
2023-06-12 English
INNATE PHARMA S.A. 6-K
Foreign Filer Report
2023-06-12 English
Informations privilégiées / Autres communiqués
Investor Presentation Classification · 1% confidence The document is a press release from Innate Pharma announcing that efficacy data for their drug lacutamab in mycosis fungoides will be presented at the 17th International Conference on Malignant Lymphoma (ICML). It details the presentation time, location, and presenter, and provides background information on the drug and the company. This type of announcement, focusing on the release of clinical data or presentation at a scientific conference, is typically classified as an Investor Presentation (IP) if it were the slides themselves, or an Earnings Release (ER) if it were summarizing financial results. Since this is an announcement about data being presented at a medical conference, and it contains substantial scientific and pipeline information aimed at investors, it aligns best with the 'Investor Presentation' (IP) category, which often encompasses key scientific updates shared with the investment community, even if it's just an announcement of the presentation itself. It is not a formal regulatory filing like 10-K or IR, nor is it a general earnings release (ER) focused on financial performance metrics. Given the focus on clinical trial data presentation, IP is the most appropriate fit among the provided options.
2023-06-12 French
Inside Information / Other news releases
Investor Presentation Classification · 1% confidence The document is a press release announcing that the company, Innate Pharma, will present updated interim efficacy results from a clinical trial (TELLOMAK Phase 2 study) at an upcoming international conference (17th International Conference on Malignant Lymphoma). This type of announcement, which details upcoming presentations of clinical data or research findings, is characteristic of an Investor Presentation (IP) or a general announcement related to investor relations/research updates. Since it is not a full financial report (10-K, IR), an earnings release (ER), or a transcript (CT), and it focuses heavily on clinical data presentation details intended for investors and researchers, 'Investor Presentation' (IP) is the most fitting category, even though it is an announcement *about* a presentation rather than the presentation itself. Given the options, IP captures the essence of disseminating detailed research/clinical progress information to the investment community.
2023-06-12 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.